UK
Dr Rebecca Sloan
She/HerI am both a qualified actuary and clinical doctor. Prior to joining LCP I was an anesthetic trainee and junior doctor for four years in the UK's National Health Service (NHS). I have worked at LCP since 2017 where I worked in the pensions actuarial department until 2021 when I joined the Health Analytics team where I specialize in value-based healthcare and women’s health.
I have experience in using a variety of actuarial modeling techniques to help clients manage and understand their risks, and financial forecasting while focusing on their long-term objectives.
Within the Health Analytics team, I use actuarial techniques and my clinical background to help decision-makers across the health sector by:
- Developing and modeling innovative reimbursement models, such as outcomes-based agreements, to align incentives around patient and population health; and
- Using a range of real-world and administrative data to provide insights into the health of the population. Recent partnerships have included the work on “The disease of disparity” report with IPPR and work alongside the RCOG on the “Left for too long” report.
LCP have a practical way of looking at things and cut through the noise on essential issues.
LCP client
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Is trade strategy part of your C-suite dialogue, and is it at a market or global level?
Natalie Rush explains why trade strategy must be a C-suite priority for pharma leaders, showing how aligning commercial, market access, and operational pathways can accelerate speed to market, control costs, and expand patient access globally.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
